HCPCS Level II code M0076 denotes prolotherapy, a therapeutic injection procedure used to stimulate soft-tissue healing and reduce musculoskeletal pain. Nationally, this code matters because prolotherapy is an outpatient, office-based interventional treatment increasingly considered in conservative management pathways for chronic tendon, ligament, and joint conditions. Proper coding ensures clinical intent is captured and supports consistent claims processing across payers.

Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage considerations and payer-specific handling, benchmark references where available, and clinical context that clarifies when prolotherapy is billed versus other injection therapies. The publication outlines common modifiers associated with this service and highlights areas where policy updates or prior authorization requirements may affect utilization and reimbursement. The summary also points to coding nuances relevant to billing staff and revenue cycle teams, and indicates where input data was not provided.